CNBC’s Angelica Peebles and Novartis CEO Vas Narasimhan join 'Squawk Box' to discuss the company's drug pipeline, managing patent cliffs, drug pricing under Trump, and more. TikTok was gone.

CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

Novartis CEO Vas Narasimhan has expressed concern over the United States' withdrawal from the World Health Organization, highlighting potential impacts on global health initiatives. These programmes, ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

Novartis CEO Vas Narasimhan outlined projections for the company's future at the 2025 JP Morgan Healthcare conference in San Francisco on 14 January. Novartis, he said, expects peak sales of over ...

The question is: Will the company take it? “We’re certainly watching the space,” Novartis CEO Vas Narasimhan, M.D., said of PD-1xVEGF bispecifics during a fourth-quarter earnings call with ...

CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and core operating income rising 29% in constant currency. For the full year, the company achieved ...

In an interview with CNBC, Novartis CEO Vas Narasimhan downplayed concerns about Entresto’s U.S. patent expiration, which could lead to increased competition from generic drugmakers. He stated ...